Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | FAAH | O00519 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6881087 | 0.96 | TSHR (0.83) | MAPTTSHRSMN1; SMN2FAAHHPGD | |
| SCHEMBL7037455 | 0.94 | TSHR (0.80) | MAPTTSHRSMN1; SMN2FAAHHPGD | |
| SCHEMBL22508718 | 0.94 | TSHR (0.80) | MAPTTSHRSMN1; SMN2FAAHHPGD | |
| SCHEMBL3459599 | 0.87 | SMN1; SMN2 (0.68) | MAPTTSHRSMN1; SMN2FAAHHPGD | |
| SCHEMBL6687715 | 0.87 | TSHR (1.00) | MAPTTSHRSMN1; SMN2FAAHHPGD | |
| SCHEMBL26092952 | 0.85 | TSHR (0.95) | MAPTTSHRSMN1; SMN2FAAHHPGD | |
| SCHEMBL25702503 | 0.85 | TSHR (0.95) | MAPTTSHRSMN1; SMN2FAAHHPGD | |
| SCHEMBL26094938 | 0.85 | TSHR (0.95) | MAPTTSHRSMN1; SMN2FAAHHPGD | |
| SCHEMBL1958588 | 0.82 | SMN1; SMN2 (0.81) | MAPTTSHRSMN1; SMN2FAAHHPGD | |
| SCHEMBL31362201 | 0.81 | MAPT (0.79) | MAPTTSHRSMN1; SMN2FAAHHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1141385-B1 | TARGET MOLECULE ATTACHMENT TO SURFACES | SURMODICS INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-7691787-B2 | Target molecule attachment to surfaces | SURMODICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20050170427-A1 | Target molecule attachment to surfaces | SURMODICS, INC. (US) | 2005-08-04 | — | — | US | disclosed |
| US-20030148308-A1 | Target molecule attachment to surfaces | SURMODICS, INC. (US) | 2003-08-07 | — | — | US | disclosed |
| US-6465178-B2 | REAGENT FOR COVALENT ATTACHMENT OF NUCLEIC ACIDS ONTO THE SURFACE OF THE SUBSTRATE, COMPRISING A POLYMER BACKBONE HAVING PENDANT THERMOCHEMICALLY REACTIVE GROUPS; MAKING ACTIVATED SLIDES FOR USE IN MICROARRAYS | SURMODICS, INC. | 2002-10-15 | — | — | US | disclosed |
| EP-1141385-A2 | TARGET MOLECULE ATTACHMENT TO SURFACES | SurModics, Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| US-20010014448-A1 | TARGET MOLECULE ATTACHMENT TO SURFACES | SURMODICS, INC. (US) | 2001-08-16 | — | — | US | disclosed |
| WO-2000040593-A2 | TARGET MOLECULE ATTACHMENT TO SURFACES | SURMODICS, INC. (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050170427-A1 | Target molecule attachment to surfaces | EPCAM, PCNA, POLM | MAPT 2776/4885TSHR 2350/4885SMN1; SMN2 4589/4885 |
| US-20010014448-A1 | TARGET MOLECULE ATTACHMENT TO SURFACES | EPCAM, PCNA, POLM | MAPT 2776/4885TSHR 2350/4885SMN1; SMN2 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.